Characterizing cellular immune response to kinetoplastid membrane protein-11 (KMP-11) during Leishmania (Viannia) panamensis infection using dendritic cells (DCs) as antigen presenting cells (APCs)

Parasite Immunology

Volumn 25, Issue 4, 2003, Pages 199-209

  Delgado, Gabriela ^a,b   Parra López, Carlos A ^a,b   Vargas, Luis Eduardo ^a   Hoya, Rubén ^a   Estupiñán, Mónica ^a   Guzmán, Fanny ^a,b   Torres, Angela ^a   Alonso, Carlos ^c,d   Velez, Iván Dario ^e   Spinel, Clara ^b   Patarroyo, Manuel E ^a,b  

^a FUNDACIÓN INSTITUTO DE INMUNOLOGÍA DE COLOMBIA FIDIC   (Colombia)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTYLGLUTAMYLGLUTAMYLPHENYLALANYLASPARAGINYLLYSYLLYSYLMETHIONYLGLUTAMINY LGLUTAMYLGLUTAMINYLALANYLLYSYLPHENYLALANYLPHENYLALANYLALANYLASPARTYLLYSYLPROLINE; CYTOKINE; EPITOPE; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 4; KINETOPLASTID MEMBRANE PROTEIN 11; MEMBRANE PROTEIN; PEPTIDE DERIVATIVE; PHENYLALANYLLYSYLHISTIDYLLYSYLPHENYLALANYLALANYLGLUTAMYLLEUCYLLEUCYLGLUTAMY LGLUTAMINYLGLUTAMINYLLYSYLALANYLGLUTAMINYLTYROSYLPROLYLSERYLLYSINE; UNCLASSIFIED DRUG; VACCINE;

ALLELE; AMINO ACID SEQUENCE; ANTIGEN PRESENTING CELL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; HUMAN; IMMUNOGENICITY; LEISHMANIA PANAMENSIS; LEISHMANIASIS; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; PROMASTIGOTE; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, PROTOZOAN; BINDING, COMPETITIVE; CASE-CONTROL STUDIES; CELL LINE; CYTOKINES; DENDRITIC CELLS; EPITOPE MAPPING; EPITOPES; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNITY, CELLULAR; LEISHMANIA GUYANENSIS; LEISHMANIASIS, MUCOCUTANEOUS; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; PROTOZOAN PROTEINS; T-LYMPHOCYTES;

KINETOPLASTIDA; LEISHMANIA PANAMENSIS; PROTOZOA;

EID: 0348140953     PISSN: 01419838     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3024.2003.00626.x     Document Type: Article

References (47)

1. Corredor A, Kreutzer RD, Tesh RB et al. Distribution and etiology of leishmaniasis in Colombia. Am J Trop Med Hyg, 1990; 42: 206-214.
2. Velez ID, Agudelo S, Robledo S et al. Diffuse cutaneous leishmaniasis with mucosal involvement in Colombia caused by an enzymatic variant of Leishmania panamensis. Trans Royal Soc Trop Med Hyg, 1994; 88: 199-199.
3. McConville MJ, Bacic A, Mitchell GF & Handman E. Lipophosphoglycan of Leishmania major that vaccinates against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor. Proc Natl Acad Sci USA, 1987; 84: 8941-8945.
4. Chang P, Chaudhuri G & Fong D. Molecular determinants of Leishmania virulence. Annu Rev Microbiol, 1990; 44: 499-529.
5. Jaffe CL, Perez L & Schnur F. Lipophosphoglycan and secreted acid phosphatase of Leishmania tropica share species-specific epitopes. Mol Biochem Parasitol, 1990; 41: 233-240.
6. Handman E & Goding JW. The Leishmania receptor for macrophages is a lipid-containing glycoconjugate. EMBO J, 1985; 4: 329-336.
7. Descoteaux A, Matlashewski G & Turco SJ. Inhibition of macrophage protein kinase C-mediated protein phosphorylation by Leishmania donovani lipophosphoglycan. J Immunol, 1992; 149: 3008-3015.
8. Turco SJ & Descoteaux A. The lipophosphoglycan of Leishmania parasites. Annu Rev Microbiol, 1992; 46: 65-94.
9. Russell DG & Alexander J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J Immunol, 1988; 140: 1274-1279.
10. Mendoca SC, Russell DG & Coutinho SG. Analysis of the human T cell responsiveness to purified antigens of Leishmania: lipophosphoglycan (LPG) and glycoprotein 63 (gp 63). Clin Exp Immunol, 1991; 83: 472-478.
11. Descoteaux A, Turco SJ, Sacks DL & Matlashewski G. Leishmania donovani lipophosphoglycan selectively inhibits signal transduction in macrophages. J Immunol, 1991; 146: 2747-2753.
12. Jardim A, Funk V, Caprioli RM & Olafson RW. Isolation and structural characterization of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoprotein. Biochem J, 1995; 305: 307-313.
13. Stebeck CE, Beecroft RP, Singh BN et al. Kinetoplastid membrane protein-11 (KMP-11) is differentially expressed during the life cycle of African trypanosomes and is found in a wide variety of kinetoplastid parasites. Mol Biochem Parasitol, 1995; 71: 1-13.
14. Tolson D, Jardim A, Schnur LF et al. The kinetoplastid membrane protein 11 of Leishmania donovani and african trypanosomes is a potent stimulator of T-lymphocyte proliferation. Infection Immunity, 1994; 62: 4893-4899.
15. Berberich C, Requena JM & Alonso C. Cloning of genes and expression and antigenicity analysis of the Leishmania infantum KMP-11 protein. Exp Parasitol, 1997; 85: 105-108.
16. Jensen ATR, Gasim S, Ismael A et al. Humoral and cellular immune responses to synthetic peptides of the Leishmania donovani kinetoplastid membrane protein-11. Scand J Immunol, 1998; 48: 103-109.
17. Ramírez JR, Berberich C, Jaramillo A, Alonso C & Velez ID. Molecular characterization of the Leishmania (Viannia) panamensis kinetoplastid membrane protein-11. Memorias do Instituto Oswaldo Cruz, 1998; 93: 247-254.
18. Trujillo C, Ramírez R, Velez ID & Berberich C. The humoral immune response to the kinetoplastid membrane protein-11 in patients with American leishmaniasis and Chagas disease: prevalence of IgG subclasses and mapping of epitopes. Immunol Lett, 1999; 70: 203-209.
19. Caro-Aguilar I, Rodriguez A, Calvo-Calle JM et al. Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens. Infection Immunity, 2002; 70: 3479-3492.
20. Olerup O & Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens, 1992; 39: 225-235.
21. Cella M, Salio M, Sakakibara Y et al. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med, 1999; 189: 821-829.
22. Merrifield RB. Solid phase peptide synthesis I. The synthesis of a tetrapeptide. J Am Chem Soc, 1963; 85: 2149-2154.
23. Sarin VK, Stephen KBJ, Tam JP & Merrifield RB. Quantitative monitoring of solid-phase peptide synthesis by the ninhydrin reaction. Anal Biochem, 1981; 117: 147-157.
24. Houghten RA. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of volunteer amino acids. Proc Natl Acad Sci USA, 1985; 82: 5131-5135.
25. Puentes F, Guzman F, Marin V et al. Leishmania: fine mapping of the Leishmanolysin molecule's conserved core domains involved in binding and internalization. Exp Parasitol, 1999; 93: 7-22.
26. Mancianti F, Falcone ML, Giannelli C & Pol A. Comparison between an enzyme-linked immunosorbent assay using a detergent-soluble Leishmania infantum antigen and indirect immunofluorescence for the diagnosis of canine leishmaniasis. Vet Parasitol, 1995; 59: 13-21.
27. Hammer J. New methods to predict MHC-binding sequences within protein antigens. Curr Opin Immunol, 1995; 7: 263-269.
28. Calvo-Calle JM, Hammer J, Sinigaglia F et al. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. J Immunol, 1997; 159: 1362-1373.
29. Imanishi T, Hanson S, Kimura A. In HLA Proceedings of the Eleventh International Histocompatibility Workshop and Conference, eds Tsuji, K, Aizaqaand, M & Sasazuki, T. Tokyo: Oxford University Press; 1991: 1065.
30. Jardim A, Alexander J, Teh HS, Ou D & Olafson RW. Immunoprotective Leishmania major synthetic T cell epitopes. J Exp Med, 1990; 172: 645-648.
31. Handman E & Mitchell GF. Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis. Proc Natl Acad Sci USA, 1985; 82: 5910-5914.
32. Jardim A, Tolson DL, Turco SJ, Pearson TW & Olafson RW. The Leishmania donovani lipophosphoglycan T lymphocyte-reactive component is a tightly associated protein complex. J Immunol, 1991; 174: 3538-3544.
33. Haberer JE, Da-Cruz AM, Soong L, Oliveira-Neto MP et al. Leishmania pifanoi amastigote antigen P-4: Epitopes involved in T-cell responsiveness in human cutaneous leishmaniasis. Infection Immunity, 1998; 66: 3100-3105.
34. Louis J, Himmelrich H, Parra-Lopez C, Tacchini-Cottier F & Launois P. Regulation of protective immunity against Leishmania major in mice. Currt Opin Immunol, 1998; 10: 459-464.
35. Thomas MC, Longobardo MV, Carmelo E et al. Mapping of the antigenic determinants of the T. cruzi kinetoplastid membrane protein-11. Identification of a linear epitope specifically recognized by human Chagasic sera. Clin Exp Immunol, 2001; 123: 465-471.
36. Isaza DM, Restrepo M & Mosca W. Immunoblot analysis of Leishmania panamensis antigens in sera of patients with American Cutaneous Leishmaniasis. J Clin Microbiol, 1997; 35: 3043-3047.
37. Boccaccio C, Jacod S, Kaiser A et al. Identification of a Clinicalgrade maturation factor for dendritic cells. J Immunotherapy, 2002; 25: 88-96.
38. Sallusto F & Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med, 1994; 179: 1109-1118.
39. Cella M, Engering A, Pinet V et al. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature, 1997; 388: 782-787.
40. Sallusto F, Cella M, Danieli C & Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med, 1995; 182: 389-400.
41. Santambrogio L, Sato AK, Carven GJ et al. Extracellular antigen processing and presentation by immature dendritic cells. Proc Natl Acad Sci USA, 1999; 96: 15056-15061.
42. Santambrogio L, Sato AK, Fisher FR et al. Abundant empty class II MHC molecules on the surface of immature dendritic cells. Extracellular antigen processing and presentation by immature dendritic cells. Proc Natl Acad Sci USA, 1999; 96: 15050-15055.
43. Kemp M, Hansen MB & Theander G. Recognition of leishmania antigens by T lymphocytes from nonexposed volunteers. Infection Immunity, 1992; 60: 2246-2251.
44. Kemp M. Regulator and effector functions of T-cell subsets in human Leishmania infections. APMIS Supplementum, 1997; 105: 5-33.
45. Gaafar A, Kharazmi A, Ismael A et al. Dichotomy of the T cell response to Leishmania antigens in patients suffering from cutaneous leishmaniasis; absence or scarcity of Th1 activity is associated with severe infections. Clin Exp Immunol, 1995; 100: 239-245.
46. Fruth U, Soliz N & Louis JA. Leishmania major interferes with antigen presentation by infected macrophages. J Immunol, 1993; 150: 1857-1864.
47. Prina E, Jouanne C, De Souza-Lao S et al. Antigen presentation capacity of murine macrophages infected with Leishmania amazonensis amastigotes. J Immunol, 1993; 151: 2050-2061.